Prevnar 13 - USA

IPR decision (Jun. 08, 2018):

AIA Review	Institution Date	Petitioner	Patent No.	Final Written Decision
IPR2017-00378; &	June 13, 2017	Merck Sharp & Dohme Corp	8,562,999	Claims 1–6, 10, 11, 14, 17, 19, 20 are unpatentable & claim 18 is patentable
IPR2017-00380	June 13, 2017	Merck Sharp & Dohme Corp	8,562,999	Claims 1–6, 10, 11, 14, 17, 19, 20 are unpatentable & claim 18 is patentable
IPR2017-00390	June 13, 2017	Merck Sharp & Dohme Corp	8,562,999	claims 7–9, 12, 13, 15, 16, 21, and 22 are unpatentable

US 8,562,999 claims  formulation comprising (i) a pH buffered saline solution with pKa of about 3.5 to about 7.5, (ii) an aluminum salt and (iii) one or more polysaccharide-protein conjugates, wherein the formulation is comprised in a siliconized container means and inhibits aggregation induced by the siliconized container means.

This patent is related to Pfizer Inc.’s top-selling Prevnar 13 pneumonia vaccine.